Tokyo Tape
Sign in
← Chiome Bioscience

Half-year report · Q2

4583.TEDINET S100U79O
Period2024-01-01 → 2024-06-30
Filed2024-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥359m2023-01-01 → 2023-06-30StandaloneNet sales
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Operating income−¥659m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥662m2023-01-01 → 2023-06-30StandaloneOrdinary income
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax−¥661m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥664m2023-01-01 → 2023-06-30StandaloneProfit loss
Total assets¥1.6bnat 2024-06-30StandaloneAssets
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥1.7bnat 2023-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥487mat 2024-06-30StandaloneLiabilities
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2023-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥595m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥82,0002023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥113m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-13.72023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio67.2%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,503,800at 2023-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥266m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-06-30−¥602m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-06-30¥209m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30−¥393m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 447
ItemContextValueUnit
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration_NonConsolidatedMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember358889000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember358889000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration_NonConsolidatedMember358889000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember-601900000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember208677000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-393223000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember-266026000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-659249000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember263728000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember263728000JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration_NonConsolidatedMember263728000JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration_NonConsolidatedMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember263728000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember263728000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration_NonConsolidatedMember263728000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember-446817000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_jpcrp040300-q2r_E26096-000DrugDiscoverySupportReportableSegmentsMember134758000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-312059000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember_ReconcilingItemsMember-269077000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-581136000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-08-13
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第21期中（自　2024年１月１日　至　2024年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社カイオム・バイオサイエンス
Company name in english cover pageFilingDateInstantChiome Bioscience Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　小林　茂
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number address of registered headquarter cover pageFilingDateInstant03-6383-3561
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区本町三丁目12番１号
Telephone number nearest place of contact cover pageFilingDateInstant03-6383-3561
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経営企画室長　美女平　在彦
Place for public inspection cover page (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass